<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively evaluated (18)fluoro-2-<z:chebi fb="0" ids="15866">deoxyglucose</z:chebi> <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (FDG-PET) scans in 172 patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system </plain></SENT>
<SENT sid="1" pm="."><plain>In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%) </plain></SENT>
<SENT sid="2" pm="."><plain>The most frequent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> diagnoses were diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LBCL; n = 51), Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>; n = 47), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL; n = 42), marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>; n = 12), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>; n = 7), and peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>; n = 5) </plain></SENT>
<SENT sid="3" pm="."><plain>FDG-PET detected disease in 100% of patients with LBCL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and in 98% of patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> and FL </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, FDG-PET detected disease in only 67% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> and 40% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtype </plain></SENT>
</text></document>